Medline (MDLN) Shares Outstanding (Weighted Average) (2024 - 2026)

Medline (MDLN) has 3 years of Shares Outstanding (Weighted Average) data on file, last reported at $819.1 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) fell 95.1% year-over-year to $819.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $819.1 million (down 95.1% YoY) and the FY2025 annual result came in at $809.7 million, changed N/A from the prior year.
• Shares Outstanding (Weighted Average) rose to $819.1 million in Q1 2026 per MDLN's latest filing, from $809.7 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $16.7 billion in Q1 2025 and bottomed at $721.0 million in Q4 2024.
• The 3-year median for Shares Outstanding (Weighted Average) is $814.4 million (2025), against an average of $4.8 billion.
• The widest annual swing landed in 2025, when Shares Outstanding (Weighted Average) gained 12.3%; it then sank 95.1% in 2026.
• Tracing MDLN's Shares Outstanding (Weighted Average) over 3 years: stood at $721.0 million in 2024, then gained by 12.3% to $809.7 million in 2025, then increased by 1.16% to $819.1 million in 2026.
• Per Business Quant, the three latest MDLN Shares Outstanding (Weighted Average) figures stand at $819.1 million (Q1 2026), $809.7 million (Q4 2025), and $16.7 billion (Q1 2025).

Peer Comparison